Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 398

1.

Impact of discordance between patient's and evaluator's global assessment on treatment outcomes in 14 868 patients with spondyloarthritis.

Michelsen B, Ørnbjerg LM, Kvien TK, Pavelka K, Nissen MJ, Nordström D, Santos MJ, Koca SS, Askling J, Rotar Z, Gudbjornsson B, Codreanu C, Loft AG, Kristianslund EK, Mann HF, Ciurea A, Eklund KK, Vieira-Sousa E, Yazici A, Jacobsson L, Tomšič M, Löve TJ, Ionescu R, van der Horst-Bruinsma IE, Iannone F, Pombo-Suarez M, Jones GT, Hyldstrup LH, Krogh NS, Hetland ML, Østergaard M.

Rheumatology (Oxford). 2020 Jan 20. pii: kez656. doi: 10.1093/rheumatology/kez656. [Epub ahead of print]

PMID:
31960053
2.

Secukinumab 150/300 mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis: 3-Year Results from the Phase 3 MEASURE 3 Study.

Pavelka K, Kivitz AJ, Dokoupilova E, Blanco R, Maradiaga M, Tahir H, Wang Y, Porter BO, Stefanska A, Richards HB, Rohrer S; MEASURE 3 study group.

ACR Open Rheumatol. 2020 Jan 20. doi: 10.1002/acr2.11102. [Epub ahead of print]

3.

Treat-to-target strategy for knee osteoarthritis. International technical expert panel consensus and good clinical practice statements.

Migliore A, Gigliucci G, Alekseeva L, Avasthi S, Bannuru RR, Chevalier X, Conrozier T, Crimaldi S, Damjanov N, de Campos GC, Diracoglu D, Herrero-Beaumont G, Iolascon G, Ionescu R, Isailovic N, Jerosch J, Lains J, Maheu E, Makri S, Martusevich N, Matucci Cerinc M, Micu M, Pavelka K, Petrella RJ, Tarantino U, Raman R.

Ther Adv Musculoskelet Dis. 2019 Dec 19;11:1759720X19893800. doi: 10.1177/1759720X19893800. eCollection 2019.

4.

Efficacy and tolerability of injectable collagen-containing products in comparison to trimecaine in patients with acute lumbar spine pain (Study FUTURE-MD-Back Pain).

Pavelka K, Jarosova H, Milani L, Prochazka Z, Kostiuk P, Kotlarova L, Meroni AM, Sliva J.

Physiol Res. 2019 Nov 22;68(Suppl 1):S65-S74.

5.

Interaction of the p.Q141K Variant of the ABCG2 Gene with Clinical Data and Cytokine Levels in Primary Hyperuricemia and Gout.

Horváthová V, Bohatá J, Pavlíková M, Pavelcová K, Pavelka K, Šenolt L, Stibůrková B.

J Clin Med. 2019 Nov 14;8(11). pii: E1965. doi: 10.3390/jcm8111965.

6.

Short-term response in new users of anti-TNF predicts long-term productivity and non-disability: analysis of Czech ATTRA ankylosing spondylitis biologic registry.

Tužil J, Mlčoch T, Jirčíková J, Závada J, Nekvindová L, Svoboda M, Uher M, Křístková Z, Vencovský J, Pavelka K, Doležal T.

Expert Opin Biol Ther. 2020 Feb;20(2):183-192. doi: 10.1080/14712598.2020.1694900. Epub 2019 Nov 25.

PMID:
31736377
7.

Imputing missing data of function and disease activity in rheumatoid arthritis registers: what is the best technique?

Mongin D, Lauper K, Turesson C, Hetland ML, Klami Kristianslund E, Kvien TK, Santos MJ, Pavelka K, Iannone F, Finckh A, Courvoisier DS.

RMD Open. 2019 Oct 17;5(2):e000994. doi: 10.1136/rmdopen-2019-000994. eCollection 2019.

8.

Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment-results from 12 countries in EuroSpA.

Brahe CH, Ørnbjerg LM, Jacobsson L, Nissen MJ, Kristianslund EK, Mann H, Santos MJ, Reino JG, Nordström D, Rotar Z, Gudbjornsson B, Onen F, Codreanu C, Lindström U, Möller B, Kvien TK, Pavelka K, Barcelos A, Sánchez-Piedra C, Eklund KK, Tomšič M, Love TJ, Can G, Ionescu R, Loft AG, van der Horst-Bruinsma IE, Macfarlane GJ, Iannone F, Hyldstrup LH, Krogh NS, Østergaard M, Hetland ML.

Rheumatology (Oxford). 2019 Oct 30. pii: kez427. doi: 10.1093/rheumatology/kez427. [Epub ahead of print]

PMID:
31665497
9.

Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaboration.

Ørnbjerg LM, Brahe CH, Askling J, Ciurea A, Mann H, Onen F, Kristianslund EK, Nordström D, Santos MJ, Codreanu C, Gómez-Reino J, Rotar Z, Gudbjornsson B, Di Giuseppe D, Nissen MJ, Pavelka K, Birlik M, Kvien T, Eklund KK, Barcelos A, Ionescu R, Sanchez-Piedra C, Tomsic M, Geirsson ÁJ, Loft AG, van der Horst-Bruinsma I, Jones G, Iannone F, Hyldstrup L, Krogh NS, Hetland ML, Østergaard M.

Ann Rheum Dis. 2019 Nov;78(11):1536-1544. doi: 10.1136/annrheumdis-2019-215427. Epub 2019 Aug 20.

PMID:
31431486
10.

Metabolites of type I, II, III, and IV collagen may serve as markers of disease activity in axial spondyloarthritis.

Hušáková M, Bay-Jensen AC, Forejtová Š, Zegzulková K, Tomčík M, Gregová M, Bubová K, Hořínková J, Gatterová J, Pavelka K, Siebuhr AS.

Sci Rep. 2019 Aug 2;9(1):11218. doi: 10.1038/s41598-019-47502-z.

11.

Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis.

Lauper K, Mongin D, Iannone F, Kristianslund EK, Kvien TK, Nordström DC, Pavelka K, Pombo-Suarez M, Rotar Z, Santos MJ, Codreanu C, Lukina G, Gale SL, John M, Luder Y, Courvoisier DS, Gabay C.

Semin Arthritis Rheum. 2019 Jun 28. pii: S0049-0172(19)30203-3. doi: 10.1016/j.semarthrit.2019.06.020. [Epub ahead of print]

12.

Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution.

Lauper K, Mongin D, Alpizar-Rodriguez D, Codreanu C, Iannone F, Kristianslund EK, Kvien TK, Pavelka K, Pombo-Suarez M, Santos MJ, Gabay C, Finckh A, Courvoisier DS.

Rheumatology (Oxford). 2019 Dec 1;58(12):2221-2229. doi: 10.1093/rheumatology/kez221.

PMID:
31209481
13.

Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice.

Bykerk VP, Östör AJK, Alvaro-Gracia J, Pavelka K, Román Ivorra JA, Nurmohamed MT, Luder Y, Sidiropoulos PNM, Devenport J, Sibilia J.

Clin Rheumatol. 2019 Sep;38(9):2411-2421. doi: 10.1007/s10067-019-04535-z. Epub 2019 Apr 26.

PMID:
31028551
14.

Serum visfatin levels in patients with axial spondyloarthritis and their relationship to disease activity and spinal radiographic damage: a cross-sectional study.

Hulejová H, Kropáčková T, Bubová K, Kryštůfková O, Filková M, Mann H, Forejtová Š, Tomčík M, Vencovský J, Pavelka K, Šenolt L.

Rheumatol Int. 2019 Jun;39(6):1037-1043. doi: 10.1007/s00296-019-04301-z. Epub 2019 Apr 25.

PMID:
31025138
15.

Functional Characterization of Clinically-Relevant Rare Variants in ABCG2 Identified in a Gout and Hyperuricemia Cohort.

Toyoda Y, Mančíková A, Krylov V, Morimoto K, Pavelcová K, Bohatá J, Pavelka K, Pavlíková M, Suzuki H, Matsuo H, Takada T, Stiburkova B.

Cells. 2019 Apr 18;8(4). pii: E363. doi: 10.3390/cells8040363.

16.

Cross-sectional study of patients with axial spondyloarthritis fulfilling imaging arm of ASAS classification criteria: baseline clinical characteristics and subset differences in a single-centre cohort.

Bubová K, Forejtová Š, Zegzulková K, Gregová M, Hušáková M, Filková M, Hořínková J, Gatterová J, Tomčík M, Szczuková L, Pavelka K, Šenolt L.

BMJ Open. 2019 Apr 2;9(4):e024713. doi: 10.1136/bmjopen-2018-024713.

17.

An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis.

Cohen S, Pablos JL, Pavelka K, Müller GA, Matsumoto A, Kivitz A, Wang H, Krishnan E.

Arthritis Res Ther. 2019 Mar 29;21(1):84. doi: 10.1186/s13075-019-1857-3.

18.

The impact of dysfunctional variants of ABCG2 on hyperuricemia and gout in pediatric-onset patients.

Stiburkova B, Pavelcova K, Pavlikova M, Ješina P, Pavelka K.

Arthritis Res Ther. 2019 Mar 20;21(1):77. doi: 10.1186/s13075-019-1860-8.

19.

Metabolites of C-reactive protein and vimentin are associated with disease activity of axial spondyloarthritis.

Siebuhr AS, Hušaková M, Forejtová S, Zegzulková K, Tomčik M, Urbanová M, Grobelná K, Gatterová J, Bay-Jensen AC, Pavelka K.

Clin Exp Rheumatol. 2019 May-Jun;37(3):358-366. Epub 2019 Feb 11.

20.

S100A11 (calgizzarin) is released by circulating mononuclear cells and its elevated plasma levels distinguish systemic lupus erythematosus patients from healthy individuals.

Cerezo LA, Šumová B, Hulejová H, Štorkánová H, Szczuková L, Tomčík M, Bečvář R, Pavelka K, Vencovský J, Závada J, Šenolt L.

Clin Exp Rheumatol. 2019 Mar-Apr;37(2):338-339. Epub 2019 Feb 4. No abstract available.

21.

Prevalence and distribution of cartilage damage at the metacarpal head level in rheumatoid arthritis and osteoarthritis: an ultrasound study.

Hurnakova J, Filippucci E, Cipolletta E, Di Matteo A, Salaffi F, Carotti M, Draghessi A, Di Donato E, Di Carlo M, Lato V, Horvath R, Komarc M, Pavelka K, Grassi W.

Rheumatology (Oxford). 2019 Jul 1;58(7):1206-1213. doi: 10.1093/rheumatology/key443.

PMID:
30690561
22.

Pro-inflammatory S100A11 is elevated in inflammatory myopathies and reflects disease activity and extramuscular manifestations in myositis.

Andrés Cerezo L, Hulejová H, Šumová B, Kropáčková T, Kryštůfková O, Klein M, Mann HF, Zámečník J, Pecha O, Pavelka K, Vencovský J, Šenolt L.

Cytokine. 2019 Apr;116:13-20. doi: 10.1016/j.cyto.2018.12.023. Epub 2019 Jan 23.

PMID:
30684913
23.

Real world use of secukinumab for treatment of axial spondyloarthritis and psoriatic arthritis: nationwide results from the ATTRA registry.

Mann HF, Závada J, Šenolt L, Bubová K, Nekvindová L, Křístková Z, Horák P, Vencovský J, Pavelka K; and the ATTRA Registry.

Clin Exp Rheumatol. 2019 Mar-Apr;37(2):342-343. Epub 2019 Jan 4. No abstract available.

24.

Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries.

Lauper K, Mongin D, Iannone F, Klami Kristianslund E, Kvien TK, Nordström D, Pavelka K, Pombo-Suarez M, Rotar Z, Santos MJ, Codreanu C, Lukina G, Courvoisier DS, Gabay C.

RMD Open. 2018 Nov 5;4(2):e000809. doi: 10.1136/rmdopen-2018-000809. eCollection 2018. Erratum in: RMD Open. 2019 Dec 23;5(2):e000809corr1.

25.

Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study.

Šumová B, Cerezo LA, Szczuková L, Nekvindová L, Uher M, Hulejová H, Moravcová R, Grigorian M, Pavelka K, Vencovský J, Šenolt L, Závada J.

Rheumatol Int. 2019 Mar;39(3):469-478. doi: 10.1007/s00296-018-4190-2. Epub 2018 Nov 3.

PMID:
30392117
26.

Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent.

Kristensen LE, Alten R, Puig L, Philipp S, Kvien TK, Mangues MA, van den Hoogen F, Pavelka K, Vulto AG.

BioDrugs. 2018 Oct;32(5):397-404. doi: 10.1007/s40259-018-0306-1.

27.

Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration.

Chatzidionysiou K, Lukina G, Gabay C, Hetland ML, Hauge EM, Pavelka K, Nordström D, Canhão H, Tomsic M, Rotar Z, Lie E, Kvien TK, van Vollenhoven RF, Saevarsdottir S.

Scand J Rheumatol. 2019 Jan;48(1):17-23. doi: 10.1080/03009742.2018.1466363. Epub 2018 Sep 27.

PMID:
30260261
28.

Lower serum clusterin levels in patients with erosive hand osteoarthritis are associated with more pain.

Kropáčková T, Šléglová O, Růžičková O, Vencovský J, Pavelka K, Šenolt L.

BMC Musculoskelet Disord. 2018 Jul 27;19(1):264. doi: 10.1186/s12891-018-2179-3.

29.

Factors associated with the orthopaedic surgeon's decision to recommend total joint replacement in hip and knee osteoarthritis: an international cross-sectional study of 1905 patients.

Huynh C, Puyraimond-Zemmour D, Maillefert JF, Conaghan PG, Davis AM, Gunther KP, Hawker G, Hochberg MC, Kloppenburg M, Lim K, Lohmander LS, Mahomed NN, March L, Pavelka K, Punzi L, Roos EM, Sanchez-Riera L, Singh JA, Suarez-Almazor ME, Dougados M, Gossec L.

Osteoarthritis Cartilage. 2018 Oct;26(10):1311-1318. doi: 10.1016/j.joca.2018.06.013. Epub 2018 Jul 11.

30.

Entheseal involvement in patients with systemic lupus erythematosus: an ultrasound study.

Di Matteo A, Filippucci E, Cipolletta E, Satulu I, Hurnakova J, Lato V, De Angelis R, Horvath R, Pavelka K, Salaffi F, Grassi W.

Rheumatology (Oxford). 2018 Oct 1;57(10):1822-1829. doi: 10.1093/rheumatology/key189.

PMID:
29982722
31.

Chronic Low Back Pain: Current Pharmacotherapeutic Therapies and a New Biological Approach.

Pavelka K, Jarosova H, Sleglova O, Svobodova R, Votavova M, Milani L, Prochazka Z, Kotlarova L, Kostiuk P, Sliva J, Meroni AM.

Curr Med Chem. 2019;26(6):1019-1026. doi: 10.2174/0929867325666180514102146. Review.

PMID:
29756567
32.

Correction to: Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial.

Durez P, Pavelka K, Lazaro MA, Garcia-Kutzbach A, Moots RJ, Amital H, Govoni M, Vastesaeger N.

Clin Rheumatol. 2018 Jul;37(7):2017-2018. doi: 10.1007/s10067-018-4131-1.

PMID:
29752584
33.

Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.

Lauper K, Nordström DC, Pavelka K, Hernández MV, Kvien TK, Kristianslund EK, Santos MJ, Rotar Ž, Iannone F, Codreanu C, Lukina G, Gale SL, Sarsour K, Luder Y, Courvoisier DS, Gabay C.

Ann Rheum Dis. 2018 Sep;77(9):1276-1282. doi: 10.1136/annrheumdis-2017-212845. Epub 2018 May 5.

PMID:
29730637
34.

Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein.

Hurnakova J, Hulejova H, Zavada J, Komarc M, Cerezo LA, Mann H, Vencovsky J, Pavelka K, Senolt L.

Clin Rheumatol. 2018 Aug;37(8):2055-2062. doi: 10.1007/s10067-018-4091-5. Epub 2018 Apr 14.

PMID:
29656372
35.

Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial.

Durez P, Pavelka K, Lazaro MA, Garcia-Kutzbach A, Moots RJ, Amital H, Govoni M, Vastesaeger N.

Clin Rheumatol. 2018 May;37(5):1417-1420. doi: 10.1007/s10067-018-4074-6. Epub 2018 Apr 2. Erratum in: Clin Rheumatol. 2018 May 12;:.

PMID:
29611083
36.

[Treat to target in gouty arthritis].

Pavelka K.

Vnitr Lek. Spring 2018;64(2):185-190. Czech.

PMID:
29595284
37.

Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.

Pavelka K, Kivitz A, Dokoupilova E, Blanco R, Maradiaga M, Tahir H, Pricop L, Andersson M, Readie A, Porter B.

Arthritis Res Ther. 2017 Dec 22;19(1):285. doi: 10.1186/s13075-017-1490-y.

38.

Mapping Quality of Life (EQ-5D) from DAPsA, Clinical DAPsA and HAQ in Psoriatic Arthritis.

Mlcoch T, Tuzil J, Sedova L, Stolfa J, Urbanova M, Suchy D, Smrzova A, Jircikova J, Hrnciarova T, Pavelka K, Dolezal T.

Patient. 2018 Jun;11(3):329-340. doi: 10.1007/s40271-017-0285-1.

PMID:
29164493
39.

[Osteoarthritis as part of metabolic syndrome?]

Pavelka K.

Vnitr Lek. Fall 2017;63(10):707-711. Review. Czech.

PMID:
29127754
40.

Biomarkers of hand osteoarthritis.

Lennerová T, Pavelka K, Šenolt L.

Rheumatol Int. 2018 May;38(5):725-735. doi: 10.1007/s00296-017-3864-5. Epub 2017 Nov 2. Review.

PMID:
29098370
41.

Functional non-synonymous variants of ABCG2 and gout risk.

Stiburkova B, Pavelcova K, Zavada J, Petru L, Simek P, Cepek P, Pavlikova M, Matsuo H, Merriman TR, Pavelka K.

Rheumatology (Oxford). 2017 Nov 1;56(11):1982-1992. doi: 10.1093/rheumatology/kex295.

PMID:
28968913
42.

Association between circulating miRNAs and spinal involvement in patients with axial spondyloarthritis.

Prajzlerová K, Grobelná K, Hušáková M, Forejtová Š, Jüngel A, Gay S, Vencovský J, Pavelka K, Šenolt L, Filková M.

PLoS One. 2017 Sep 22;12(9):e0185323. doi: 10.1371/journal.pone.0185323. eCollection 2017.

43.

Changes of patient-reported outcomes and protein fingerprint biomarkers after exercise therapy for axial spondyloarthritis.

Husakova M, Siebuhr AS, Pavelka K, Spiritovic M, Bay-Jensen AC, Levitova A.

Clin Rheumatol. 2019 Jan;38(1):173-179. doi: 10.1007/s10067-017-3802-7. Epub 2017 Aug 30.

PMID:
28856518
44.

Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study.

Hurnakova J, Hulejova H, Zavada J, Hanova P, Komarc M, Mann H, Klein M, Sleglova O, Olejarova M, Forejtova S, Ruzickova O, Vencovsky J, Pavelka K, Senolt L.

PLoS One. 2017 Aug 23;12(8):e0183420. doi: 10.1371/journal.pone.0183420. eCollection 2017.

45.

Treatment of atlanto-axial subluxation secondary to rheumatoid arthritis by short segment stabilization with polyaxial screws.

Vanek P, Bradac O, de Lacy P, Pavelka K, Votavova M, Benes V.

Acta Neurochir (Wien). 2017 Sep;159(9):1791-1801. doi: 10.1007/s00701-017-3274-1. Epub 2017 Jul 27.

PMID:
28752203
46.

Interleukin-20 is triggered by TLR ligands and associates with disease activity in patients with rheumatoid arthritis.

Šenolt L, Prajzlerová K, Hulejová H, Šumová B, Filková M, Veigl D, Pavelka K, Vencovský J.

Cytokine. 2017 Sep;97:187-192. doi: 10.1016/j.cyto.2017.06.009. Epub 2017 Jun 26.

PMID:
28662439
47.

Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.

Pavelka K, Akkoç N, Al-Maini M, Zerbini CAF, Karateev DE, Nasonov EL, Rahman MU, Pedersen R, Dinh A, Shen Q, Vasilescu R, Kotak S, Mahgoub E, Vlahos B.

Rheumatol Int. 2017 Sep;37(9):1469-1479. doi: 10.1007/s00296-017-3749-7. Epub 2017 Jun 9.

PMID:
28597306
48.

Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study.

Cohen S, Genovese MC, Choy E, Perez-Ruiz F, Matsumoto A, Pavelka K, Pablos JL, Rizzo W, Hrycaj P, Zhang N, Shergy W, Kaur P.

Ann Rheum Dis. 2017 Oct;76(10):1679-1687. doi: 10.1136/annrheumdis-2016-210459. Epub 2017 Jun 5.

49.

Correction: The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.

Moots RJ, Xavier RM, Mok CC, Rahman MU, Tsai WC, Al-Maini MH, Pavelka K, Mahgoub E, Kotak S, Korth-Bradley J, Pedersen R, Mele L, Shen Q, Vlahos B.

PLoS One. 2017 Jun 5;12(6):e0179308. doi: 10.1371/journal.pone.0179308. eCollection 2017.

50.

Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT).

Reginster JY, Dudler J, Blicharski T, Pavelka K.

Ann Rheum Dis. 2017 Sep;76(9):1537-1543. doi: 10.1136/annrheumdis-2016-210860. Epub 2017 May 22.

Supplemental Content

Loading ...
Support Center